Eli Lilly and Incyte Present New Data of Olumiant (baricitinib) in P-III BREEZE-AD5 Trial Moderate to Severe Atopic Dermatitis at AAD2021
Shots: The new analyses of the P-III BREEZE-AD5 trial and an extended safety analysis across multiple trials for Olumiant (2mg, qd) vs PBO in patients […]